Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis
Nishioka, Y.; Kitada, O.; Meguro, T.; Aragane, K.; Tanimukai, T.; Nakamura, H.; Nakahama, H.; Matsuyama, T.; Sugita, M.; Yano, T.; Takenaka, Y.; Takamitsu, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(4): 527-530
1999
ISSN/ISBN: 0385-0684 PMID: 10097751 Document Number: 502578
A 61-year-old man with chronic renal failure caused by polycystic kidney disease requiring hemodialysis three times weekly developed small cell carcinoma of the lung. The patient received combination chemotherapy with nedaplatin (50 mg) and etoposide (50 mg). Blood levels were monitored, showing that nedaplatin was more dialyzable than cisplatin. The patient achieved a complete response. These results suggest that nedaplatin-etoposide combination chemotherapy may be safer than cisplatin-containing regimen for patients with chronic renal failure hemodialysis and that a satisfactory response can be expected.